November 13, 2009 11:43 AM
- Text
As Boehringer Develops Viagra for Women, History Suggests High Risk of Failure
(MoneyWatch) Boehringer Ingelheim is developing a female version of Viagra -- and wading into an infamous graveyard of failed pharma products. Like cures for obesity, therapies to boost flagging libido in women are better known for their failures than their successes.
Boehringer's entry is flibanserin, another failed antidepressant that works on serotonin. (Interestingly, Johnson & Johnson (JNJ) is also repurposing a failed antidepressant, dapoxetine, for premature ejaculation in men.)
Boehringer has developed a bunch of cutesy names for its clinical trials: "Violet," "Daisy," "Dahlia" and "Orchid." Together they comprise the "Bouquet" studies, Bloomberg reports. (Insert your own joke about petals opening here.)
Now Boehringer has gotten the proper Georgia O'Keefe references down, can it get the chemistry right? History says no. The fact that this is an antidepressant tells you it is likely to come along with a number of unpleasant side effects.
More importantly, every other company that has tried this category has failed, despite the insistence that somewhere in this thicket is a $2 billion business.
Here's the ever-growing list of products that have either not yet succeeded or not been popular, in addition to flibanserin:
Boehringer's entry is flibanserin, another failed antidepressant that works on serotonin. (Interestingly, Johnson & Johnson (JNJ) is also repurposing a failed antidepressant, dapoxetine, for premature ejaculation in men.)Boehringer has developed a bunch of cutesy names for its clinical trials: "Violet," "Daisy," "Dahlia" and "Orchid." Together they comprise the "Bouquet" studies, Bloomberg reports. (Insert your own joke about petals opening here.)
Now Boehringer has gotten the proper Georgia O'Keefe references down, can it get the chemistry right? History says no. The fact that this is an antidepressant tells you it is likely to come along with a number of unpleasant side effects.
More importantly, every other company that has tried this category has failed, despite the insistence that somewhere in this thicket is a $2 billion business.
Here's the ever-growing list of products that have either not yet succeeded or not been popular, in addition to flibanserin:
- Palatin Technologies is developing bremelanotide, an injected therapy.
- Pfizer (PFE) abandoned research into Viagra for women prior to 2003, according to BMJ.
- BioSante Pharmaceuticals is working on another testosterone skin patch, LibiGel.
- Zestra is an OTC product now owned by Semprae Labs.
- Berkeley Premium Neutraceuticals markets Avlimil, but it's a scam.
- Related:
- Pfizer Rep Claims Zoloft Touted for Failed Cheerleaders; Viagra for Women
- Study: P&G's Intrinsa Doesn't Work; Reflects Badly on Noven and Pharma Unit Sale
- Noven and P&G Try "Viagra for Women" Despite History of Failure
- Will P&G Pharma Auction End the Company's Pursuit of "Viagra for Women"?
Latest Now in MoneyWatch
- Nationwide foreclosure pact gains momentum
- Board shake-up at Yahoo
- Fed: Consumer borrowing sees strong growth
- Greek debt talks drag on, banks signal progress
- Dow approaches 13,000, one rally from a record
- Market braces for federal budget battle
- How to handle passive aggressive employees | Leila's House of Corrections
- 4 ways to overcome price resistance on sales
- New York, Calif. holding out foreclosure settlement
- Bernanke sticks with low-rate policy at hearing
- Job openings up: Here's how to get one yourself
- Apple patent throws wrench into Facebook plans
- Yum! Brands forecasts strong expansion overseas
- Cash balance retirement plans: Annuity options
- Tax prep tips: Jill Schlesinger makes it easy
- Why is Greece negotiating over debt when it could be dictating?
- Job openings jump to a near 3-year high
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Oil rises to near $99 after US crude supply drop
- Asia stocks up following surge on Wall Street
- Asia stocks up following surge on Wall Street
- Pa. House nears vote on gas drilling fee bill
on Facebook Most Discussed Stories
on CBS News






